These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Welti M; Dimitriou F; Gutzmer R; Dummer R Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428582 [TBL] [Abstract][Full Text] [Related]
5. The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study. Haist M; Stege H; Ebner R; Fleischer MI; Loquai C; Grabbe S Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565212 [TBL] [Abstract][Full Text] [Related]
6. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related]
7. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946 [TBL] [Abstract][Full Text] [Related]
10. BRAF and MEK inhibition in melanoma. Dossett LA; Kudchadkar RR; Zager JS Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338 [TBL] [Abstract][Full Text] [Related]
11. Which adjuvant treatment for patients with BRAF Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557 [TBL] [Abstract][Full Text] [Related]
12. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703 [TBL] [Abstract][Full Text] [Related]
13. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma. Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681 [TBL] [Abstract][Full Text] [Related]
14. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658 [TBL] [Abstract][Full Text] [Related]
15. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. Viñal D; Martinez D; Espinosa E Clin Transl Oncol; 2019 Aug; 21(8):1061-1066. PubMed ID: 30607792 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE Front Immunol; 2021; 12():661737. PubMed ID: 34025662 [TBL] [Abstract][Full Text] [Related]